Your browser is no longer supported. Please, upgrade your browser.
Yumanity Therapeutics, Inc.
Index- P/E- EPS (ttm)-14.09 Insider Own0.60% Shs Outstand10.30M Perf Week-17.11%
Market Cap38.25M Forward P/E- EPS next Y-4.56 Insider Trans0.00% Shs Float8.93M Perf Month-62.53%
Income-52.90M PEG- EPS next Q-1.02 Inst Own36.20% Short Float1.80% Perf Quarter-67.46%
Sales14.20M P/S2.69 EPS this Y6.70% Inst Trans-13.27% Short Ratio0.72 Perf Half Y-77.60%
Book/sh3.15 P/B1.09 EPS next Y-38.50% ROA- Target Price27.67 Perf Year-83.14%
Cash/sh4.17 P/C0.82 EPS next 5Y- ROE- 52W Range3.40 - 26.20 Perf YTD-79.76%
Dividend- P/FCF- EPS past 5Y2.40% ROI-76.60% 52W High-86.87% Beta0.53
Dividend %- Quick Ratio2.70 Sales past 5Y9.80% Gross Margin- 52W Low1.18% ATR0.47
Employees46 Current Ratio2.70 Sales Q/Q- Oper. Margin- RSI (14)14.31 Volatility13.01% 9.65%
OptionableYes Debt/Eq0.45 EPS Q/Q69.10% Profit Margin- Rel Volume1.10 Prev Close3.48
ShortableYes LT Debt/Eq0.27 Earnings- Payout- Avg Volume223.55K Price3.44
Recom1.70 SMA20-33.34% SMA50-55.31% SMA200-72.07% Volume245,783 Change-1.15%
Dec-03-21 06:00PM  
Nov-16-21 04:30PM  
Nov-15-21 07:30AM  
Nov-12-21 04:05PM  
Nov-10-21 07:00AM  
Oct-14-21 07:00AM  
Sep-09-21 04:15PM  
Aug-16-21 07:00AM  
Aug-12-21 04:15PM  
Aug-06-21 07:00AM  
Jun-14-21 07:00AM  
May-27-21 07:00AM  
May-17-21 04:05PM  
May-13-21 07:00AM  
May-12-21 08:00AM  
May-04-21 08:00AM  
Apr-28-21 08:07PM  
Apr-22-21 07:00AM  
Apr-13-21 08:00AM  
Apr-06-21 08:00AM  
Mar-31-21 08:48AM  
Mar-23-21 09:41AM  
Mar-09-21 08:00AM  
Mar-02-21 04:05PM  
Feb-10-21 08:00AM  
Jan-06-21 08:00AM  
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.